SAO PAULO, July 26 (Reuters) – China National Pharmaceutical Team Co Ltd (Sinopharm) (CNPHG.UL) has used for emergency use authorization for its COVID-19 vaccine in Brazil, the Brazilian overall health agency Anvisa explained in a assertion on Monday.
Brazil now employs one more Chinese COVID-19 vaccine, Sinovac Biotech’s (SVA.O) Coronavac, which is the vaccine most administered in the South American country.
Sinopharm’s vaccine is created from an inactivated virus, Anvisa stated, and is suggested for people in excess of age 18. The agency additional that it is used in two doses, with an interval of three to 4 months among them, citing details supplied by the company.
The agency stated that it will evaluation about the next working day whether or not the documentation submitted by Sinopharm is complete and that it may possibly request further info to approach the crisis-use software.
Reporting by Anthony Boadle
Producing by Ana Mano
Modifying by Jonathan Oatis and Will Dunham
Our Benchmarks: The Thomson Reuters Have confidence in Rules.